Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer
Experimental drug to treat liver cancer shows evidence of activity with manageable side effects
27 October 2022Large stroke trial finds intensive blood pressure lowering after clot removal worsens recovery
28 October 2022Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer
Preliminary data from a phase I clinical trial of a new drug called NVL-520 for patients with non-small cell lung cancer (NSCLC) and other solid tumors, suggest that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change, and to reach cancer cells in the brain, with very few side effects.
